Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic interstitial pneumonia and has a median survival after diagnosis of 2–5 years. Pirfenidone is the first approved antifibrotic drug for the treatment of IPF. Here we report the functional progress, side effects and survival...

Descripción completa

Detalles Bibliográficos
Autores principales: Vietri, Lucia, Cameli, Paolo, Perruzza, Marco, Cekorja, Behar, Bergantini, Laura, d’Alessandro, Miriana, Refini, Rosa Metella, Pieroni, Maria, Fossi, Antonella, Bennett, David, Spalletti, Marco, Mazzei, Maria Antonietta, Sestini, Piersante, Rottoli, Paola, Bargagli, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7029533/
https://www.ncbi.nlm.nih.gov/pubmed/32066332
http://dx.doi.org/10.1177/1753466620906326

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7029533/
https://www.ncbi.nlm.nih.gov/pubmed/32066332
http://dx.doi.org/10.1177/1753466620906326

Ejemplares similares